Positron Emission Tomography Based Elucidation of the Enhanced Permeability and Retention Effect in Dogs with Cancer Using Copper-64 Liposomes.
暂无分享,去创建一个
Andreas Kjær | Thomas L Andresen | T. Andresen | A. Kjær | J. Henriksen | D. Elema | A. Kristensen | A. E. Hansen | Palle Rasmussen | Anncatrine L Petersen | Anders E Hansen | Per Munck af Rosenschöld | Jonas R Henriksen | Betina Boerresen | Dennis R Elema | Annemarie T Kristensen | Palle H Rasmussen | A. L. Petersen | P. M. af Rosenschöld | Betina Boerresen
[1] M. Paoloni,et al. Translation of new cancer treatments from pet dogs to humans , 2008, Nature Reviews Cancer.
[2] R. Gillies,et al. Evolutionary dynamics of carcinogenesis and why targeted therapy does not work , 2012, Nature Reviews Cancer.
[3] J. Seo,et al. Positron emission tomography imaging of the stability of Cu-64 labeled dipalmitoyl and distearoyl lipids in liposomes. , 2011, Journal of controlled release : official journal of the Controlled Release Society.
[4] D. Connolly,et al. Tumor vascular permeability factor stimulates endothelial cell growth and angiogenesis. , 1989, The Journal of clinical investigation.
[5] Christopher J. Cheng,et al. Nanomedicine: Downsizing tumour therapeutics. , 2012, Nature nanotechnology.
[6] C. Presant,et al. Successful imaging of human cancer with indium‐111‐labeled phospholipid vesicles , 1988, Cancer.
[7] C. Presant,et al. Preliminary report: imaging of Kaposi sarcoma and lymphoma in AIDS with indium-111-labelled liposomes , 1990, The Lancet.
[8] J. Folkman,et al. Fundamental concepts of the angiogenic process. , 2003, Current molecular medicine.
[9] H. Maeda,et al. Exploiting the enhanced permeability and retention effect for tumor targeting. , 2006, Drug discovery today.
[10] J. Kopeček,et al. The Influence of Cytotoxicity of Macromolecules and of VEGF Gene Modulated Vascular Permeability on the Enhanced Permeability and Retention Effect in Resistant Solid Tumors , 2004, Pharmaceutical Research.
[11] K. Syrigos,et al. Influence of tumour size on uptake of111In-DTPA-labelled pegylated liposomes in a human tumour xenograft model , 2000, British Journal of Cancer.
[12] Robert Langer,et al. Preclinical Development and Clinical Translation of a PSMA-Targeted Docetaxel Nanoparticle with a Differentiated Pharmacological Profile , 2012, Science Translational Medicine.
[13] Jun Fang,et al. The EPR effect: Unique features of tumor blood vessels for drug delivery, factors involved, and limitations and augmentation of the effect. , 2011, Advanced drug delivery reviews.
[14] M. Dewhirst,et al. Overcoming limitations in nanoparticle drug delivery: triggered, intravascular release to improve drug penetration into tumors. , 2012, Cancer research.
[15] R. Vile,et al. Effective targeting of solid tumors in patients with locally advanced cancers by radiolabeled pegylated liposomes. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.
[16] S. Gambhir. Molecular imaging of cancer with positron emission tomography , 2002, Nature Reviews Cancer.
[17] Andreas Kjær,et al. Positron emission tomography evaluation of somatostatin receptor targeted 64Cu-TATE-liposomes in a human neuroendocrine carcinoma mouse model. , 2012, Journal of controlled release : official journal of the Controlled Release Society.
[18] J. Willmann,et al. Molecular imaging in drug development , 2008, Nature Reviews Drug Discovery.
[19] D. Hanahan,et al. Hallmarks of Cancer: The Next Generation , 2011, Cell.
[20] E. Hoffman,et al. Application of annihilation coincidence detection to transaxial reconstruction tomography. , 1975, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[21] J. Paterson,et al. Liposomal distribution in malignant glioma: possibilities for therapy. , 1997, Nuclear medicine communications.
[22] A. Gabizon. Stealth liposomes and tumor targeting: one step further in the quest for the magic bullet. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.
[23] Andreas Kjær,et al. 64Cu loaded liposomes as positron emission tomography imaging agents. , 2011, Biomaterials.
[24] A. Bangham. Surrogate cells or Trojan horses. The discovery of liposomes. , 1995, BioEssays : news and reviews in molecular, cellular and developmental biology.
[25] You Han Bae,et al. Tumor heterogeneity and its implication for drug delivery. , 2012, Journal of controlled release : official journal of the Controlled Release Society.
[26] H. Maeda,et al. A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs. , 1986, Cancer research.
[27] I. Law,et al. FDG PET/CT imaging in canine cancer patients. , 2011, Veterinary radiology & ultrasound : the official journal of the American College of Veterinary Radiology and the International Veterinary Radiology Association.
[28] L. Zhang,et al. Nanoparticles in Medicine: Therapeutic Applications and Developments , 2008, Clinical pharmacology and therapeutics.
[29] Tamar Safra. Cardiac safety of liposomal anthracyclines. , 2003, The oncologist.
[30] H. Maeda,et al. Polymeric drugs for efficient tumor-targeted drug delivery based on EPR-effect. , 2009, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.
[31] W. Phillips,et al. Delivery of gamma-imaging agents by liposomes. , 1999, Advanced drug delivery reviews.
[32] Y. Barenholz. Doxil®--the first FDA-approved nano-drug: lessons learned. , 2012, Journal of controlled release : official journal of the Controlled Release Society.